Apellis Pharmaceuticals Reports Second Quarter 2019 Business Update and Financial Results
July 31, 2019 17:00 ET
|
Apellis Pharmaceuticals, Inc.
Completed Enrollment in Phase 3 Paroxysmal Nocturnal Hemoglobinuria (PNH) Head-to-Head Study in Patients Treated with Eculizumab; Top-line Data Anticipated in December 2019 Expects to Initiate Phase...
Apellis Pharmaceuticals Expands Leadership Team, Appoints Lucia Celona as Chief People Officer
July 22, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., July 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Will Commence APL-9 Program to Control the Complement System in Host Responses to AAV Vector Administration for Gene Therapies
July 18, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., July 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
June 27, 2019 07:39 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress
June 15, 2019 10:00 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2019 17:30 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass. and CRESTWOOD, Ky., May 24, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
May 17, 2019 08:00 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., May 17, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results
May 08, 2019 07:00 ET
|
Apellis Pharmaceuticals, Inc.
Resumed Dosing in Phase 3 Geographic Atrophy Program Announced Innovative Collaboration & Financing with SFJ Pharmaceuticals® Cash Position of $288.2 Million at Quarter-End WALTHAM Mass. and...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2019 16:30 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass. and CRESTWOOD, Ky., April 05, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2019 16:30 ET
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., and CRESTWOOD, Ky., March 22, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...